<DOC>
	<DOCNO>NCT01094275</DOCNO>
	<brief_summary>Clopidogrel , inhibitor ADP induce platelet aggregation activation , one commonly use drug patient cardiovascular disease . The specific aim propose study determine whether interaction proton-pump inhibitor ( PPIs ) clopidogrel dependent CYP2C19 haplotype .</brief_summary>
	<brief_title>Role CYP2C19 Polymorphism Drug Interaction Between Clopidogrel Omeprazole</brief_title>
	<detailed_description>Clopidogrel , inhibitor ADP induce platelet aggregation activation , one commonly use drug patient cardiovascular disease ; coronary-stenting would possible without robust anti platelet function drug . Clopidogrel pro-drug transformed series hepatic cytochrome p-450 ( CYP ) enzymes active metabolite . One CYP enzymes , 2C19 subject competitive inhibition commonly use proton-pump inhibitor ( PPIs ) . PPIs commonly use gastro-esophageal protection patient treat clopidogrel . Around 63 % 3,799 patient clopidogrel receive PPI TMH 2008 . Recently , series publication indicate clopidogrel active metabolite level platelet inhibition low patient receive PPIs . In addition , recent survey &gt; 16,690 patient Medco database indicate use PPIs associate 51 % increase risk death myocardial infarction patient receive clopidogrel . Recent data also indicate patient loss function ( LOF ) haplotypes CYP2C19 gene low level active metabolite dose clopidogrel . These patient high rate death , myocardial infarction , stent thrombosis ischemic complication patient wild type enzyme . Inadequate response clopidogrel therapy implicate important predictor adverse clinical event . The reported prevalence non-responsiveness clopidogrel among patient cardiovascular disease 4 % 34 % , depend method definition use assess parameter . Approximately 25 % American population carry LOF mutation CYP2C19 . It unclear whether concomitant use omeprazole ( PPI ) clopidogrel would result decrease platelet function parameter CYP2C19 clopidogrel activation pathway . The specific aim propose study determine whether interaction PPIs clopidogrel dependent CYP2C19 haplotype . We hypothesize among subject LOF genotype , interaction clopidogrel PPIs great subject wild type genotype7 manifest platelet function parameter conversion clopidogrel active metabolite . Approximately 75 randomly select healthy volunteer subject screen intent identify least 16 subject heterozygous LOF mutation CYP2C19 ( know *2/rs4244285 , *3 ) . Subjects LOF allele select along age gender-matched wild type control baseline platelet function study perform ( n=16 group ) . Subjects stratum randomly assign receive one week clopidogrel combination omeprazole clopidogrel alone . Subjects initially assign clopidogrel + omeprazole take clopidogrel subject initially assign clopidogrel take clopidogrel omeprazole .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<criteria>age 18 65 healthy take drug / counter drug regularly . ability commitment take drug volunteer 3 blood draw . Taking scheduled medication know affect platelet function clopidogrel NSAIDS11 , COX2 inhibitor , beta blocker , calcium channel blocker , diuretic , anticoagulant , old psychotropic agent , recent ingestion alcohol caffeine Known history heart disease Bleeding disorder Known allergy contraindication omeprazole clopidogrel Pregnant nursing woman also exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>drug resistance</keyword>
	<keyword>gene polymorphism</keyword>
</DOC>